Data / Drug companies / Direct RX
Direct RX: 81 products in the FDA NDC directory, labeler code 61919
Direct RX (labeler code 61919) lists 81 products in the FDA National Drug Code Directory, covering 60 finished drugs by generic name. By type: 81 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on March 16, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 61919
- Products in commercial distribution
- 81
- Packages
- 179
- Finished drugs by generic name
- 60
- Prescription products
- 81
- Over the counter products
- 0
- Controlled substance products
- Schedule II 1, Schedule III 2, Schedule IV 9
- Started marketing in the last 12 months
- 1
- Products with a marketing end date set
- 1
- Earliest marketing start
- January 1, 2014
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 78 | 96.3% |
| New drug applications (NDA) | 2 | 2.5% |
| Authorized generics (NDA) | 1 | 1.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 81 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 31 | 38.3% |
| Capsule | 20 | 24.7% |
| Tablet, film coated | 9 | 11.1% |
| Tablet, extended release | 5 | 6.2% |
| Cream | 4 | 4.9% |
| Ointment | 3 | 3.7% |
| Solution/ drops | 2 | 2.5% |
| Tablet, delayed release | 1 | 1.2% |
| Patch | 1 | 1.2% |
| Tablet, film coated, extended release | 1 | 1.2% |
| Tablet, orally disintegrating | 1 | 1.2% |
| Powder, for suspension | 1 | 1.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Triamcinolone Acetonide | 61919-234 | Cream | Generic drugs (ANDA) | March 16, 2026 |
| Topiramate | 61919-213 | Tablet | Generic drugs (ANDA) | April 17, 2024 |
| Bupropion HCL ER (XL) | 61919-558 | Tablet, extended release | Generic drugs (ANDA) | February 15, 2024 |
| Nitrofurantoin Macrocrystals | 61919-842 | Capsule | Generic drugs (ANDA) | February 7, 2024 |
| Mirtazapine | 61919-153 | Tablet, film coated | Generic drugs (ANDA) | May 10, 2022 |
| Divalproex sodium | 61919-249 | Tablet, delayed release | Generic drugs (ANDA) | April 6, 2022 |
| Furosemide | 61919-255 | Tablet | Generic drugs (ANDA) | October 21, 2021 |
| Nortriptyline hydrochloride | 61919-353 | Capsule | Generic drugs (ANDA) | September 15, 2021 |
| Triamcinolone acetonide | 61919-619 | Ointment | Generic drugs (ANDA) | February 4, 2021 |
| Metoprolol succinate | 61919-334 | Tablet, extended release | Generic drugs (ANDA) | January 19, 2021 |
| Furosemide | 61919-242 | Tablet | Generic drugs (ANDA) | June 18, 2020 |
| Dexamethasone | 61919-827 | Tablet | Generic drugs (ANDA) | June 15, 2020 |
| Lidocaine | 61919-588 | Patch | Authorized generics (NDA) | May 12, 2020 |
| Metaxalone | 61919-832 | Tablet | Generic drugs (ANDA) | January 6, 2020 |
| Diazepam | 61919-409 | Tablet | Generic drugs (ANDA) | November 18, 2019 |
| Metaxalone | 61919-832 | Tablet | Generic drugs (ANDA) | August 29, 2019 |
| Ondansetron | 61919-565 | Tablet, film coated | Generic drugs (ANDA) | August 22, 2019 |
| Ibuprofen | 61919-463 | Tablet, film coated | Generic drugs (ANDA) | August 22, 2019 |
| Oxycodone and acetaminophen | 61919-871 | Tablet | Generic drugs (ANDA) | August 21, 2019 |
| Metronidazole | 61919-032 | Tablet, film coated | Generic drugs (ANDA) | August 21, 2019 |
| Zolpidem tartrate | 61919-751 | Tablet | Generic drugs (ANDA) | August 19, 2019 |
| Cyclobenzaprine hydrochloride | 61919-261 | Tablet, film coated | Generic drugs (ANDA) | August 16, 2019 |
| Cephalexin | 61919-606 | Capsule | Generic drugs (ANDA) | August 14, 2019 |
| Tizandine | 61919-811 | Tablet | Generic drugs (ANDA) | August 13, 2019 |
| Sulfameth/Trimeth-DS | 61919-645 | Tablet | Generic drugs (ANDA) | August 13, 2019 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.